MINNEAPOLIS–(BUSINESS WIRE)–Yukon Partners (“Yukon”), a provider of mezzanine capital for middle market private equity transactions, is pleased to announce its investment in Crossroads Treatment Centers (“Crossroads” or the “Company”), a portfolio company of Revelstoke Capital Partners (“Revelstoke”).

“Yukon has a long history of working with Revelstoke and has known Crossroads for several years. We are excited to support Revelstoke and the Crossroads management team as they continue to expand their footprint and provide this essential treatment to an underserved population”

Crossroads, based in Greenville, South Carolina, is a premier provider of medication assisted treatment services in the United States. Crossroads provides both methadone and suboxone medication assisted treatment through its outpatient programs. Since partnering with Revelstoke, Crossroads has expanded its number of clinics from 9 to 94 in an effort to deliver effective and affordable treatment for persons suffering from opioid use disorder.

“Yukon has a long history of working with Revelstoke and has known Crossroads for several years. We are excited to support Revelstoke and the Crossroads management team as they continue to expand their footprint and provide this essential treatment to an underserved population,” said Michael Hall, Managing Partner of Yukon.

“Crossroads has quintupled since our investment in the Company and we are very excited about the Company’s prospects. With Yukon’s investment, the Company will have additional capital for continued growth initiatives including acquisitions, new clinic expansion and tele-health initiatives,” said Simon Bachleda, Co-Founder and Managing Partner of Revelstoke.

This article originally appeared in an article in BusinessWire.